Brokerages Set Establishment Labs Holdings Inc. (NASDAQ:ESTA) PT at $87.14

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $87.1429.

ESTA has been the subject of a number of analyst reports. TD Cowen reissued a “buy” rating on shares of Establishment Labs in a report on Monday, June 8th. Canaccord Genuity Group boosted their price target on Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 26th. BTIG Research boosted their price target on Establishment Labs from $88.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Finally, Wall Street Zen downgraded Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th.

Establishment Labs Stock Performance

Establishment Labs stock opened at $84.81 on Friday. Establishment Labs has a 52 week low of $33.35 and a 52 week high of $86.00. The company has a market capitalization of $2.50 billion, a price-to-earnings ratio of -56.92 and a beta of 1.11. The stock has a 50-day moving average price of $71.23 and a 200 day moving average price of $69.70. The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The company had revenue of $59.88 million during the quarter, compared to analyst estimates of $57.40 million. During the same period in the previous year, the firm posted ($0.70) earnings per share. The company’s revenue was up 44.7% compared to the same quarter last year. Sell-side analysts anticipate that Establishment Labs will post -1.07 EPS for the current year.

Insider Buying and Selling at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the completion of the transaction, the director directly owned 927,504 shares of the company’s stock, valued at $69,952,351.68. This represents a 10.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders sold 330,000 shares of company stock worth $22,854,538. Corporate insiders own 9.99% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ESTA. KBC Group NV acquired a new position in shares of Establishment Labs during the 1st quarter worth approximately $28,000. Quarry LP acquired a new position in shares of Establishment Labs during the 3rd quarter worth approximately $34,000. Kestra Advisory Services LLC acquired a new position in shares of Establishment Labs during the 4th quarter worth approximately $47,000. State of Wyoming acquired a new position in shares of Establishment Labs during the 3rd quarter worth approximately $71,000. Finally, Osaic Holdings Inc. raised its stake in shares of Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares during the period. 72.91% of the stock is owned by institutional investors and hedge funds.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.